Aeglea BioTherapeutics Inc.

1.50-0.0400-2.60%Vol 137.87K1Y Perf -79.19%
May 18th, 2022 15:09 DELAYED
BID1.50 ASK1.51
Open1.50 Previous Close1.54
Pre-Market- After-Market-
 - -%  - -
Target Price
10.25 
Analyst Rating
Strong Buy 1.00
Potential %
583.33 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★     51.03
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.91 
Earnings Rating
Strong Buy
Market Cap91.76M 
Earnings Date
9th May 2022
Alpha-0.02 Standard Deviation0.19
Beta1.60 

Today's Price Range

1.431.51

52W Range

1.298.50

5 Year PE Ratio Range

-2.80-4.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
14.07%
1 Month
-18.95%
3 Months
-49.34%
6 Months
-76.49%
1 Year
-79.19%
3 Years
-76.23%
5 Years
-74.92%
10 Years
-

TickerPriceChg.Chg.%
AGLE1.50-0.0400-2.60
AAPL140.41-8.8263-5.91
GOOG2 260.73-73.2964-3.14
MSFT254.24-11.9600-4.49
XOM90.36-1.7470-1.90
WFC42.09-1.6250-3.72
JNJ176.35-2.4700-1.38
FB193.55-9.0700-4.48
GE75.25-1.1500-1.51
JPM120.16-2.0250-1.66
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.35-0.37-5.71
Q04 2021-0.32-0.313.12
Q03 2021-0.29-0.31-6.90
Q02 2021-0.19-0.1047.37
Q01 2021-0.13-0.28-115.38
Q04 2020-0.29-0.34-17.24
Q03 2020-0.38-0.2923.68
Q02 2020-0.39-0.40-2.56
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.2727.03Positive
9/2022 QR-0.2734.15Positive
12/2022 FY-1.163.33Positive
12/2023 FY-1.0421.21Positive
Next Report Date-
Estimated EPS Next Report-0.35
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume137.87K
Shares Outstanding61.17K
Shares Float56.61M
Trades Count1.38K
Dollar Volume202.87K
Avg. Volume402.73K
Avg. Weekly Volume335.55K
Avg. Monthly Volume336.90K
Avg. Quarterly Volume535.74K

Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) stock closed at 1.54 per share at the end of the most recent trading day (a 7.69% change compared to the prior day closing price) with a volume of 128.10K shares and market capitalization of 91.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 87 people. Aeglea BioTherapeutics Inc. CEO is Anthony G. Quinn.

The one-year performance of Aeglea BioTherapeutics Inc. stock is -79.19%, while year-to-date (YTD) performance is -67.58%. AGLE stock has a five-year performance of -74.92%. Its 52-week range is between 1.29 and 8.5, which gives AGLE stock a 52-week price range ratio of 2.91%

Aeglea BioTherapeutics Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.37, a price-to-sale (PS) ratio of 4.35, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -58.37%, a ROC of -73.74% and a ROE of -77.69%. The company’s profit margin is -%, its EBITDA margin is -349.50%, and its revenue ttm is $20.10 Million , which makes it $0.33 revenue per share.

Of the last four earnings reports from Aeglea BioTherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.35 for the next earnings report. Aeglea BioTherapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aeglea BioTherapeutics Inc. is Strong Buy (1), with a target price of $10.25, which is +583.33% compared to the current price. The earnings rating for Aeglea BioTherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aeglea BioTherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aeglea BioTherapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 7.93, ATR14 : 0.18, CCI20 : -10.35, Chaikin Money Flow : -0.10, MACD : -0.20, Money Flow Index : 23.89, ROC : 6.94, RSI : 42.65, STOCH (14,3) : 73.53, STOCH RSI : 1.00, UO : 48.10, Williams %R : -26.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aeglea BioTherapeutics Inc. in the last 12-months were: Anthony G. Quinn (Buy at a value of $667 620), Armen Shanafelt (Buy at a value of $549 692), Jonathan Alspaugh (Buy at a value of $604 660)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aeglea BioTherapeutics Inc.

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

CEO: Anthony G. Quinn

Telephone: +1 512 942-2935

Address: 805 Las Cimas Parkway, Austin 78746, TX, US

Number of employees: 87

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

79%21%

Bearish Bullish

65%35%

Bearish Bullish

66%34%

TipRanks News for AGLE

Tue, 08 Mar 2022 17:45 GMT Aeglea Biotherapeutics (AGLE) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits